“The greatest danger in times of turbulence is not the turbulence — it is to act with yesterday’s logic.” — Peter Drucker

The dietary supplement industry is not in crisis. It is in transition. The real risk is not turbulence, it is clinging to a framework built for a different era while the marketplace evolves at speed.

A CEO launches a novel ingredient backed by millions in R&D investment. Six months later, the FDA issues guidance suggesting it may require NDI notification — or worse, be drug-precluded. Marketing claims that pass legal review trigger a warning letter, forcing reformulation or withdrawal. A competitor operating through offshore fulfillment undercuts pricing by 40% while making claims that no compliant brand could substantiate. Meanwhile, California, New York, and Massachusetts each propose different labeling standards for the same product category.

This is not a hypothetical scenario. It reflects the operating environment created by three decades of market evolution without statutory modernization.

For more than 30 years, the dietary supplement industry has defended the Dietary Supplement Health and Education Act (DSHEA) as the foundation of its growth. That defense has been justified. DSHEA preserved consumer access, protected innovation, and prevented supplements from being regulated like drugs. But the market DSHEA was designed for no longer exists.

Today’s industry operates in a world of global supply chains, cross-border e-commerce, synthetic bioidenticals, fermentation platforms, and SKU proliferation at scale. Yet the FDA still lacks a basic, comprehensive, authoritative list of products in commerce. Enforcement remains reactive. Ingredient interpretations evolve through guidance. Claim boundaries shift in warning letters rather than in statutes.

The widening gap between modern commerce and outdated regulatory infrastructure harms responsible supplement companies, while bad actors who have no interest in compliance reap the benefits. And without DSHEA modernization, the harm to the supplement industry will only increase, and exponentially so.

DSHEA Modernization is Coming, Whether You Participate or Not

Without DSHEA modernization:

• Enforcement volatility will increase
• States will fill perceived federal gaps
• Platforms will impose de facto compliance standards
• Perceived risk by investors will rise
• Poorly thought-out political intervention will accelerate due to increases in safety events

When oversight appears inadequate, pressure builds. When enforcement appears uneven, critics gain leverage. When statutory clarity is missing, discretion expands. Eventually, so much harm will be done to the supplement industry that Congress will have no choice but to act. By that point, though, industry will likely have lost the ability to meaningfully shape the DHSEA reform.

Senator Dick Durbin’s listing legislation has already been reintroduced with support from some major industry groups. Listing requirements are coming. The strategic question is whether they arrive in isolation or whether industry takes this opportunity to shape comprehensive DSHEA reform, including issues like ingredient certainty, claims pathways, and federal preemption, while it still can.

This is not reform versus status quo. It is structured modernization with guardrails versus continued expansion through enforcement drift.

Visibility Is Competitive Strategy

Mandatory post-market listing often triggers resistance. But from a CEO’s perspective, the issue is competitive.

The proposal requires responsible persons to list products within 30 days of marketing. It preserves post-market timing. It prohibits premarket approval. It bars the FDA from conditioning marketing on listing content. It limits the required information to label data.

In exchange, the marketplace becomes more visible.

Today, compliant firms compete against brands operating beyond the FDA’s radar. Those actors suppress pricing, distort competition, and damage category credibility when enforcement catches up.

Opacity is not freedom. It is a competitive distortion.

A visible marketplace raises the cost of non-compliance and protects firms that have already invested in substantiation and quality systems.

The valuation implications are real. Private equity firms increasingly flag regulatory opacity as enterprise risk. When FDA receives only a fraction of expected ingredient notifications relative to product growth, investors anticipate unpredictable enforcement.

Transparency creates competitive moats. Platform scrutiny, investor diligence, and FDA enforcement become more efficient at targeting bad actors. Firms with nothing to hide benefit.

If you are building long-term brand equity, transparency works in your favor.

Ingredient Certainty Is Capital Preservation

Drug preclusion and ingredient ambiguity are balance-sheet issues.

The NAC and vinpocetine controversies illustrate the problem. Ingredients marketed for years face an uncertain status because investigational drug activity never produced approved products. Companies invest in manufacturing, marketing, and distribution only to see the legal status shift through interpretation rather than statute. That uncertainty distorts long-term planning, delays capital allocation, and depresses valuation multiples.

The proposed listing act would narrow drug preclusion to genuine overlap and establish safety pathways for bioidenticals. It would reset the grandfather list through formal rulemaking.

This converts interpretive volatility into statutory clarity. Capital flows toward industries with durable rules. It hesitates where they are discretionary.

Claims Reform Is Risk Compression

The current claims environment rewards semantics over clarity. Add a qualifier and exposure changes. Remove it, and scrutiny follows. Disclaimers proliferate without meaning.

The proposal would establish structured lanes for OTC-aligned disease claims under defined conditions. It would remove mandatory disclaimers for structure/function claims while retaining them for disease claims.

This is not reckless expansion. It is defined as architecture.

Clear lanes reduce enforcement unpredictability. Reduced unpredictability protects brand value. Protected brand value supports long-term valuation.

Claims modernization is about volatility reduction.

Stronger Oversight Prevents Overcorrection

Some executives fear that stronger oversight invites expansion. History suggests the opposite.

Major regulatory expansions have historically followed crises — from the Federal Food, Drug, and Cosmetic Act of 1938 to the 1962 Kefauver-Harris Amendments to the post-ephedra serious adverse-event reporting law.

Underfunded oversight increases the probability of backlash.

The Act would authorize dedicated appropriations while prohibiting premarket expansion and preserving post-market structure. It would sunset funding and codify limits.

Structured modernization reduces the likelihood of reactionary legislation.

A Political Reality CEOs Cannot Ignore

On Capitol Hill, supplement trade associations are perceived as divided. When one major association supports listing reform and another opposes it, legislators conclude the industry resists oversight improvement on principle.

Fragmentation weakens influence. If your company has invested in compliance and transparency, opposing visibility may protect your least responsible competitors more than it protects you.

Executive engagement, not passive delegation, will shape outcomes.

The Bottom Line: Risk, Valuation, and Control

This is not merely a compliance discussion. It is a control discussion.

Modernization through statute means defined authority, codified limits, and structured reform. Modernization through drift means expanding discretion, unpredictable costs, and fragmented oversight.

In one scenario, CEOs shape the framework. In the other, they operate within it.

The supplement industry has matured into a sector worth tens of billions of dollars. Markets of this scale do not remain indefinitely governed by guidance and improvisation. They either upgrade statutory infrastructure, or have it imposed.

There is a timing window. The FDA has acknowledged modernization needs. Legislative vehicles are active. Industry support exists in key segments. That alignment will not last forever.

If the industry fails to coalesce around structured reform, the alternative is erosion through enforcement, fragmentation, and ultimately crisis-driven legislation.

Modernizing DSHEA is not capitulation. It is preservation. CEOs who recognize this inflection point will shape the next 30 years of supplement regulation. The rest will operate within it.

The question is not whether change is coming. The question is whether the industry shapes it or waits to react.

“Control your own destiny or someone else will.” — Jack Welch